IPF Recruiting Phase 2 Trials for Tipelukast (DB12435)

IndicationStatusPhase
DBCOND0050181 (IPF)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02503657Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Treatment